Oral Ghrelin Receptor Blockers for Diabetes and Obesity: Quinazolinone Drug Candidates
Orally active quinazolinone-based ghrelin receptor antagonists reduced food intake and improved glucose tolerance in animal models, advancing toward clinical development for combined diabetes and obesity treatment.
Quick Facts
What This Study Found
Quinazolinone ghrelin receptor antagonists showed oral bioavailability, reduced food intake, and improved glucose tolerance in animal models — positioning orally active ghrelin blockade as a dual-mechanism drug approach for treating both diabetes and obesity simultaneously.
Key Numbers
How They Did This
animal-study study on ghrp, weight-loss.
Why This Research Matters
Relevant for ghrp, weight-loss, diabetes.
The Bigger Picture
Advances peptide research.
What This Study Doesn't Tell Us
See abstract.
Questions This Raises
- ?Further research needed.
- ?Clinical translation to evaluate.
Trust & Context
- Key Stat:
- Key finding Quinazolinone ghrelin receptor antagonists showed oral bioavailability, reduced food intake, and improved glucose tolerance in animal models — positio
- Evidence Grade:
- moderate evidence.
- Study Age:
- Published in 2007.
- Original Title:
- Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity.
- Published In:
- Journal of medicinal chemistry, 50(21), 5202-16 (2007)
- Authors:
- Rudolph, Joachim, Esler, William P, O'connor, Stephen, Coish, Philip D G, Wickens, Philip L, Brands, Michael, Bierer, Donald E, Bloomquist, Brian T, Bondar, Georgiy, Chen, Libing, Chuang, Chih-Yuan, Claus, Thomas H, Fathi, Zahra, Fu, Wenlang, Khire, Uday R, Kristie, James A, Liu, Xiao-Gao, Lowe, Derek B, McClure, Andrea C, Michels, Martin, Ortiz, Astrid A, Ramsden, Philip D, Schoenleber, Robert W, Shelekhin, Tatiana E, Vakalopoulos, Alexandros, Tang, Weifeng, Wang, Lei, Yi, Lin, Gardell, Stephen J, Livingston, James N, Sweet, Laurel J, Bullock, William H
- Database ID:
- RPEP-01285
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What was studied?
Oral Ghrelin Receptor Blockers for Diabetes and Obesity: Quinazolinone Drug Candidates
What was found?
Orally active quinazolinone-based ghrelin receptor antagonists reduced food intake and improved glucose tolerance in animal models, advancing toward clinical development for combined diabetes and obesity treatment.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-01285APA
Rudolph, Joachim; Esler, William P; O'connor, Stephen; Coish, Philip D G; Wickens, Philip L; Brands, Michael; Bierer, Donald E; Bloomquist, Brian T; Bondar, Georgiy; Chen, Libing; Chuang, Chih-Yuan; Claus, Thomas H; Fathi, Zahra; Fu, Wenlang; Khire, Uday R; Kristie, James A; Liu, Xiao-Gao; Lowe, Derek B; McClure, Andrea C; Michels, Martin; Ortiz, Astrid A; Ramsden, Philip D; Schoenleber, Robert W; Shelekhin, Tatiana E; Vakalopoulos, Alexandros; Tang, Weifeng; Wang, Lei; Yi, Lin; Gardell, Stephen J; Livingston, James N; Sweet, Laurel J; Bullock, William H. (2007). Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity.. Journal of medicinal chemistry, 50(21), 5202-16.
MLA
Rudolph, Joachim, et al. "Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity.." Journal of medicinal chemistry, 2007.
RethinkPeptides
RethinkPeptides Research Database. "Quinazolinone derivatives as orally available ghrelin recept..." RPEP-01285. Retrieved from https://rethinkpeptides.com/research/rudolph-2007-quinazolinone-derivatives-as-orally
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.